Stockscreener 앱 받기
1.695
58.29%
-2.285
전일 마감가:
$3.98
열려 있는:
$2.12
하루 거래량:
23.72M
Relative Volume:
21.95
시가총액:
$95.22M
수익:
-
순이익/손실:
$-131.52M
주가수익비율:
-0.9522
EPS:
-1.78
순현금흐름:
$-107.56M
1주 성능:
+7.79%
1개월 성능:
+12.93%
6개월 성능:
+87.06%
1년 성능:
+38.33%
1일 변동 폭
$1.53
$2.20
1주일 범위
$1.43
$4.22
52주 변동 폭
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
명칭
Prelude Therapeutics Inc
전화
(302) 467-1280
주소
175 INNOVATION BOULEVARD, WILMINGTON
PRLD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.6823 | 225.27M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.08 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.04 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.57 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.16 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 개시 | Jefferies | Buy |
| 2022-03-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-28 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-10-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-26 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2020-11-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Goldman | Neutral |
| 2020-10-20 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
Incyte (INCY) Secures $935M Deal with Prelude Therapeutics for J - GuruFocus
Major Shift in PRLD Stock: What’s Behind the Surge? - StocksToTrade
Prelude Therapeutics (PRLD) Stock’s Wild Ride: 150% Surge, Big Pharma Deal & What’s Next - ts2.tech
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates - Benzinga
Prelude loses CMO, pauses SMARCA2 degraders and bags $60M from Incyte - Fierce Biotech
Incyte inks option agreement with Prelude for JH2 inhibitor program - Seeking Alpha
Prelude Therapeutics Signs Option Agreement with Incyte - TipRanks
Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today? - TipRanks
Prelude Therapeutics pauses clinical development of SMARCA2 degrader program (PRLD:NASDAQ) - Seeking Alpha
Prelude Therapeutics Announces Management Changes - TradingView
Prelude to prioritize JAK2V617F JH2 inhibitor, KAT6A selective degrader programs - TipRanks
Prelude Therapeutics CMO Jane Huang departs - TipRanks
PRLD's Financial Outlook: Cash Runway Extended to 2027 - GuruFocus
Incyte (INCY) Secures Option for JAK2V617F Program in $910M Deal - GuruFocus
Incyte (INCY) Secures Exclusive Option on JAK2V617F Program - GuruFocus
Prelude Therapeutics sees cash runway into 2027 - TipRanks
Prelude Therapeutics pauses development of SMARCA2 degrader program - TipRanks
Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte - Investing.com Nigeria
Prelude Therapeutics shifts focus to JAK2 and KAT6A programs - Investing.com
A Look at Prelude Therapeutics Inc (PRLD) Shares in the Recent Past Indicates Growth - setenews.com
Incyte Enters Exclusive Option Agreement to Acquire Prelude Therapeutics' JAK2V617F Inhibitor Program for MPNs - Quiver Quantitative
Prelude Therapeutics Announces Strategic Business Update - GlobeNewswire
Prelude (NASDAQ: PRLD) grants Incyte option on JAK2V617F; $60M, $100M on exercise - Stock Titan
Is Prelude Therapeutics Incorporated stock supported by innovation pipelineJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
Can Prelude Therapeutics Incorporated stock sustain free cash flow growth2025 Price Targets & AI Enhanced Trading Signals - newser.com
Can Prelude Therapeutics Incorporated stock hit analyst price targetsMarket Weekly Review & Safe Capital Growth Tips - newser.com
Will Prelude Therapeutics Incorporated stock deliver shareholder valueSwing Trade & Safe Investment Capital Preservation Plans - newser.com
What institutional flow reveals about Prelude Therapeutics IncorporatedMarket Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Prelude Therapeutics (PRLD) Projected to Post Earnings on Wednesday - Defense World
Prelude Therapeutics Spikes: Can The Pipeline Keep Up? - RTTNews
Prelude Therapeutics (NASDAQ:PRLD) and CytoDyn (OTCMKTS:CYDY) Financial Analysis - Defense World
Prelude Therapeutics: A Subtle Shift In Pipeline Underscores Funding Challenges - Seeking Alpha
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Prelude Therapeutics (PRLD) to Present Preclinical Findings at A - GuruFocus
Prelude Therapeutics announces publication of abstracts for ASH meeting - TipRanks
Is Prelude Therapeutics Incorporated stock ready for a breakoutQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Prelude Therapeutics Announces Publication of Abstracts for - GlobeNewswire
Pattern recognition hints at Prelude Therapeutics Incorporated upsideJuly 2025 Market Mood & Stepwise Swing Trade Plans - newser.com
What to do if you’re stuck in Prelude Therapeutics IncorporatedJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
Is Prelude Therapeutics Incorporated stock a defensive play in 2025Bond Market & Real-Time Market Sentiment Alerts - newser.com
How Prelude Therapeutics Incorporated stock reacts to oil pricesJuly 2025 Movers & High Accuracy Swing Entry Alerts - newser.com
Volume spikes in Prelude Therapeutics Incorporated stock – what they meanJuly 2025 Recap & Technical Pattern Based Buy Signals - newser.com
Can Prelude Therapeutics Incorporated stock maintain operating marginsJuly 2025 Snapshot & Consistent Income Trade Recommendations - newser.com
Is Prelude Therapeutics Incorporated stock supported by strong fundamentalsPortfolio Performance Report & High Return Trade Guides - newser.com
Prelude Therapeutics Shares Surge on Analyst Optimism and Upcoming Earnings - AD HOC NEWS
Prelude Therapeutics Incorporat (PRLD) stock forecast and price target - Yahoo! Finance UK
What sentiment indicators say about Prelude Therapeutics Incorporated stockWatch List & Verified Technical Trade Signals - newser.com
Using flow based indicators on Prelude Therapeutics IncorporatedDip Buying & Safe Entry Zone Tips - newser.com
How to build a custom watchlist for Prelude Therapeutics Incorporated2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Prelude Therapeutics Inc (PRLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
0.35%
자본화:
|
볼륨(24시간):